Provided by Tiger Trade Technology Pte. Ltd.

Fulcrum Therapeutics

9.74
+0.19001.99%
Post-market: 9.740.00000.00%18:23 EST
Volume:489.20K
Turnover:4.77M
Market Cap:642.55M
PE:-8.52
High:10.00
Open:9.71
Low:9.62
Close:9.55
52wk High:15.74
52wk Low:2.32
Shares:65.97M
Float Shares:39.39M
Volume Ratio:1.08
T/O Rate:1.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1430
EPS(LYR):-0.1569
ROE:-31.21%
ROA:-20.63%
PB:3.24
PE(LYR):-62.08

Loading ...

Fulcrum Therapeutics Grants 70,000 Stock Options to New Employee

Reuters
·
14 hours ago

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
14 hours ago

Director Robert J. Gould Reports Sale of Fulcrum Therapeutics Inc. Common Shares

Reuters
·
Feb 05

Truist Financial Sticks to Their Buy Rating for Fulcrum Therapeutics (FULC)

TIPRANKS
·
Feb 02

Fulcrum and Kpmg Announce Collaboration to Transform Utility Field Operations and Strengthen Operational Resiliency

THOMSON REUTERS
·
Jan 27

De-Risked Efficacy and Clean Safety for Pociredir in Sickle Cell Disease Position FULC for Re-Rating Ahead of 1Q26 Data

TIPRANKS
·
Jan 26

Fulcrum Therapeutics (FULC) Receives a Sell from Bank of America Securities

TIPRANKS
·
Jan 16

Fulcrum Therapeutics Showcases Pociredir's Promise as Best-in-Class Oral Therapy for Sickle Cell Disease

Reuters
·
Jan 14

Analysts Have Conflicting Sentiments on These Healthcare Companies: Fulcrum Therapeutics (FULC), Teladoc (TDOC) and MDxHealth (MDXH)

TIPRANKS
·
Jan 13

Fulcrum Therapeutics updates strategy on lead sickle cell therapy

TIPRANKS
·
Jan 12

Fulcrum Therapeutics Initiated at Overweight by JP Morgan

Dow Jones
·
Jan 12

JPMorgan Initiates Coverage on Fulcrum Therapeutics With Overweight Rating, $20 Price Target

MT Newswires Live
·
Jan 12

Fulcrum Therapeutics Inc : JP Morgan Initiates Coverage With Overweight Rating; Price Target $20

THOMSON REUTERS
·
Jan 12

Fulcrum Therapeutics Grants Stock Options to New Employees

Reuters
·
Jan 10

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jan 10

Director Robert J. Gould Reports Sale of Fulcrum Therapeutics Inc. Common Shares

Reuters
·
Jan 07

Chief Legal Officer Curt Oltmans Reports Sale of Fulcrum Therapeutics Common Shares

Reuters
·
Dec 18, 2025

Fulcrum Therapeutics Is Maintained at Buy by Truist Securities

Dow Jones
·
Dec 12, 2025

RA Capital Management Reports Sale of Fulcrum Therapeutics Common Shares

Reuters
·
Dec 11, 2025

BRIEF-Fulcrum Therapeutics Announces Pricing Of Upsized $175.0 Million Public Offering Of Common Stock And Pre-Funded Warrants

Reuters
·
Dec 10, 2025